Results 11 to 20 of about 23,901 (228)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis [PDF]

Drug, Healthcare and Patient Safety, 2011
E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine member of the ...
Lewiecki EM
doaj   +2 more sources

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis [PDF]

Endocrinology and Metabolism, 2015
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased ...
Yong-Ki Min
doaj   +2 more sources

Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? [PDF]

, 2021
The prevalence of sarcopenia with osteoporosis results in a higher risk of falling and fractures. It was noted that patients who had completed their planned 5-year denosumab therapy course as treatment for these conditions started to sustain falls.
Hegazi, Mohamed Osama, Aroussy, Nadia El, Almedany, Samah, Bahlas, Sami, Gaafary, Maha El, Galal, S., Hassan, Waleed, Egyptian Academy of Bone Health, Metabolic Bone Diseases, Nasr, Annie, Toth, Mathias, Miedany, Yasser El, Yasser El Miedany, Maha El Gaafary, Annie Nasr, Sami Bahlas, Samah Almedany, null null, Mathias Toth, Waleed Hassan, Salwa Galal, Nadia El Aroussy, Mohamed Osama Hegazi   +21 more
core   +1 more source

Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3-Year Prospective Study. [PDF]

J Cachexia Sarcopenia Muscle
ABSTRACT Background Osteoporosis and sarcopenia frequently coexist in older adults, yet whether denosumab provides muscle‐related benefits beyond bone remains uncertain. We compared denosumab and zoledronic acid across functional, imaging, biologic and study‐defined sarcopenia outcomes based on an Asian Working Group for Sarcopenia (AWGS) 2025‐informed
Li X, Yuan Z, Ma N, Huang B, Tao H, Chen S.   +5 more
europepmc   +2 more sources

Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. [PDF]

, 2021
BACKGROUND Denosumab discontinuation without subsequent bisphosphonates (BPs) is associated with bone loss and multiple vertebral fractures. OBJECTIVE Identifying risk factors for bone loss and vertebral fractures after denosumab discontinuation.
Everts-Graber, J, Gahl, Brigitta, Reichenbach, Stephan, Ziswiler, H R, Lehmann, T, Studer, U, S. Reichenbach, U. Studer, T. Lehmann, H.R. Ziswiler, B. Gahl, J. Everts-Graber   +11 more
core   +3 more sources

Denosumab [PDF]

mAbs, 2009
Denosumab is an anti-receptor activator of nuclear factor (NF)-kappaB (RANK) ligand human monoclonal antibody studied as a treatment for postmenopausal osteoporosis (PMO) and bone destruction due to rheumatoid arthritis (RA) or metastatic cancers. As of February 2009, the candidate was undergoing US Food and Drug Administration review, and might be ...
openaire   +2 more sources

Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

Frontiers in Oncology, 2020
Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of ...
Hengyuan Li, Hengyuan Li, Junjie Gao, Junjie Gao, Youshui Gao, Nong Lin, Minghao Zheng, Zhaoming Ye   +7 more
doaj   +1 more source

Does denosumab exert a protective effect against COVID-19? Results of a large cohort study

Frontiers in Endocrinology, 2023
IntroductionDenosumab is a monoclonal antibody blocking the receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand (RANK/RANKL) pathway, thus inhibiting osteoclastogenesis.
Sara Cassibba, Silvia Ippolito, Silvia Pellegrini, Silvia Pellegrini, Roberto Trevisan, Roberto Trevisan, Alessandro Rossini   +6 more
doaj   +1 more source

Denosumab in men receiving androgen-deprivation therapy for prostate cancer [PDF]

, 2009
Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of ...
Szwedowski, M., Smith, MR, Kupic, A, Tammela, T.L., Saad, F, Denosumab, HALT Prostate Cancer Study Group, Goessl, C, Feldman, R, Tammela, TL, Hernández Toriz, N., Ke, C, Szwedowski, M, Goessl, C., Leder, B.Z., Heracek, J, Kupic, A., Ke, C., Egerdie, B., Heracek, J., Leder, BZ, Hernández Toriz, N, Egerdie, B, Saad, F., Feldman, R., Smith, M.R., Lippuner, Kurt   +25 more
core   +1 more source

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Journal of Bone Oncology, 2022
Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple
Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck   +8 more
doaj   +1 more source